Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.54 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7275905 | 0.94 | TSHR (0.58) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL80140 | 0.86 | TSHR (0.55) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL1004267 | 0.85 | LOXL2 (0.64) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL9666850 | 0.83 | TSHR (0.61) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL6393589 | 0.83 | TSHR (0.61) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL10569888 | 0.80 | TSHR (0.68) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL9640908 | 0.80 | TSHR (0.62) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL531 | 0.80 | LOXL2 (0.58) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL9666965 | 0.80 | KCNJ1 (0.44) | LOXL2CYP2A6KCNJ1KCNH2TSHR | |
| SCHEMBL9666970 | 0.80 | KCNJ1 (0.44) | LOXL2CYP2A6KCNJ1KCNH2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101253160-A | Improved process for the preparation of letrozole | SICOR INC (US) | 2008-08-27 | — | — | CN | claimed |
| CN-1049157-A | The preparation method of cycloalkanylpyrrole | SCHERING AG (DE) | 1991-02-13 | — | — | CN | claimed |
| CN-118702604-B | Sulfonium salt single-molecule resin type photoresist containing stilbene structure, and preparation method and application thereof | 中国科学院理化技术研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-118702604-A | Sulfonium salt single-molecule resin type photoresist containing stilbene structure, and preparation method and application thereof | 中国科学院理化技术研究所 | 2024-09-27 | — | — | CN | disclosed |
| WO-2024145659-A1 | HETEROCYCLE FUSED GAMMA-CARBOLINES ACTING ON THE SEROTONINE 5-HT2A RECEPTOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230100186-A1 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2023-03-30 | — | — | US | disclosed |
| CN-108463460-B | Microbiocidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-11447481-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-09-20 | — | — | US | disclosed |
| CN-110225911-B | Oxadiazolone transient receptor potential channel inhibitors | 豪夫迈·罗氏有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2022-03-01 | — | — | US | disclosed |
| CN-108137570-B | Microbicidal oxadiazole derivatives | 先正达参股股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-1990005133-A1 | MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1990-05-17 | — | — | WO | disclosed |
| EP-0364123-A1 | Muscarinic receptor antagonists | Pfizer Limited (GB) | 1990-04-18 | — | — | EP | disclosed |
| US-4885293-A | CARBOXYALKYL DIPEPTIDES | SCHERING CORPORATION (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0195817-B1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
| US-4826816-A | Antihypertensive compounds | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4634698-A | TOPICAL HYPOTENSIVES | SCHERING CORPORATION (US) | 1987-01-06 | — | — | US | disclosed |
| CN-85108623-A | Preparation has the novel method of the heterocycleamide of medical active | — | 1986-07-30 | — | — | CN | disclosed |
| US-4556655-A | TREATMENT OF CARDIOVASCULAR DISORDERS AND GLAUCOMA | SCHERING CORPORATION (US) | 1985-12-03 | — | — | US | disclosed |
| EP-0052437-A1 | Antibacterial compounds, processes for their preparation and compositions containing them | BEECHAM GROUP PLC (GB) | 1982-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230100186-A1 | FENTANYL HAPTENS FOR THE PREPARATION OF A FENTANYL VACCINE | OPRL1, OPRK1, CYP2F1 | LOXL2 4590/4885CYP2A6 9/4885KCNJ1 2703/4885 |
| US-11447481-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG2 | LOXL2 276/4885CYP2A6 621/4885KCNJ1 3343/4885 |
| US-11259524-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | LOXL2 278/4885CYP2A6 452/4885KCNJ1 3450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.